Enhanced Naloxone delivery with a unique dosage form.

Pinova Therapeutics is developing a simple, cost effective and ready-to-use Naloxone product.

Learn MoreAbout Us
70,000+
Opioid Overdose Deaths
Every 6-7 minutes, someone in America dies from an opioid overdose. There were over 70,000 opioid overdose deaths in 2020.
35,000,000+
At Risk of An Overdose
This population comprises about 19M high-impact chronic pain patients taking higher doses of opioids, about 11M misusing heroin or fentanyl primarily to alleviate pain, and others on opioid use disorder treatments.
140,000,000+
Opioid Prescriptions Written
142,816,781 opioid prescriptions were written in 2020. This corresponds to a dispensing rate of 43.3 prescriptions per 100 persons.
01
About

We have patented a novel Naloxone dosage form.

A startup with a big vision and mission. We have enhanced Naloxone delivery with our unique dosage form. Our goal is to price for access and affordability. No one need die from an opioid overdose.

02
OTC Naloxone

Why Over-the-Counter Naloxone?

Pinova Therapeutics is answering that call for OTC Naloxone to remove the critical barriers that exist:

Stigma:

Even if someone can afford to pay the current high retail price, walking up to the pharmacy counter and asking for it is difficult.

Pharmacist Confusion:

Many pharmacists are still confused whether they can dispense Naloxone without a prescription under State standing orders. Often the supervisor is called and a prolonged discussion is needed.

price

Critical to have low-cost affordable Naloxone for consumers and institutions.

03
IN THE NEWS

Press Releases & News

NaxSwab™ OTC novel naloxone nasal swab successfully administered by children and adults to potentially rescue someone from an opioid overdose in study.
Human Factors Validation Study demonstrated that adolescents and adults could follow the instructions to correctly administer NaxSwab™ OTC in a simulated emergency environment
Read more >
Naloxone Startup Pursues FDA Approval for Over-the-Counter Swab.
The FDA has encouraged pharmaceutical companies to apply for approval for over-the-counter versions of naloxone to combat the overdose crisis from bootleg fentanyl.
Read more >
NaxSwab™ OTC novel naloxone nasal swab demonstrates faster absorption and higher early exposures against other naloxone products in clinical study.
Pharmacokinetic study data in healthy volunteers shows NaxSwab™ OTC has 74% and 1096% higher exposures at 2.5 minutes compared to naloxone HCI 4mg nasal spray and 0.4mg IM naloxone injection
Read more >